Meeting global demand for a potential COVID-19 treatment is more than any one company can handle on its own. Acknowledging that reality, Japanese drugmaker Fujifilm has picked partners for its offering.
Fujifilm has struck a three-way deal with India’s Dr. Reddy’s Laboratories and Dubai-based Global Response Aid to manufacture and sell its flu drug Avigan (favipiravir) for potential treatment of COVID-19, the company said Wednesday.
The drug is already approved for COVID-19 in India and Russia. The new agreement covers all countries other than Japan, China and Russia.
Specifically, for an unidentified lump-sum license fee and royalties on sales, Fujifilm is granting Dr. Reddy’s and GRA access to Avigan’s preclinical and clinical data to help run their own studies. Dr. Reddy’s gains exclusive rights to the drug in India.
In addition, Fujifilm will transfer its manufacturing method exclusively to Dr. Reddy’s, which will establish production of the drug and utilize GRA’s global sales network to supply the med.
Avigan was originally developed against influenza pandemics. It gained global attention when Japanese Prime Minister Shinzo Abe touted it as a potential COVID-19 treatment.
With that government support, a fast-track approval in Japan was initially expected in May. But clinical research on the drug suddenly slowed down as COVID-19 cases dropped in Japan. A month ago, Nikkei Asian Review reported that completion of the trial would instead come in July at the earliest, as it has only hit around 70% of the enrollment goal.
Back in April, amid speculation around Avigan’s potential in COVID-19 and its side effects, including birth defects, Fujifilm said it would increase monthly production of Avigan up to 100,000 treatment courses by July, about 2.5 times more than its level at the beginning of March.
On June 20, India’s Glenmark Pharmaceuticals won a local go-ahead to market a generic version of Avigan, which it’s selling under the brand FabiFlu, for the treatment of mild to moderate COVID-19 patients.
Meanwhile, Gilead Sciences has also signed on multiple partners for FDA-authorized COVID-19 drug remdesivir, including India’s Cipla and Hetero Labs and Jubilant Life Sciences.
By: Angus Liu
Source: Fierce Pharma
As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.
McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.
AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.